|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 27, 2017 ) According to the report Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market, published by Market Data Forecast, the market is projected to reach USD 1906 Billion by 2021, at a CAGR of 14.3% from 2016 to 2021.
Nuclear medicines are fundamentally drugs that contain radioactive components for radionuclide-transmitting ionizing radiations. Their core application lies in the determination and treatment of different ailments that ordinary prescriptions fail to accomplish. Radiopharmaceuticals are extraordinary as they are utilized to directly target particular organs in the body where the medication can transmit radiations. These radiations are then caught by gamma cameras put in vicinity of the patient. The radiation measurement in these drugs is kept as low as conceivable to avoid the reactions of radiation exposure.
Radiopharmaceuticals are controlled inside a patient's body through various courses, including oral, inhalation, or infusion. This to a great extent relies upon the idea of the components being utilized and the organ that is targeted. Radiopharmaceuticals can help in the analysis of the blood stream in cerebrum cells, heart pumping rate and working system of kidney cells. Radiopharmaceuticals are utilized as a part of the diagnosis of mental diseases, such as Parkinson's disease and Alzheimer's, and additionally help pinpoint the location of tumors or minute bone fractures in a body.
Get a comprehensive overview of the Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market: http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/
Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market: Drivers & Restraints
Increasing incidence of chronic diseases such as cancer and cardiac ailments, advancements in technology, increasing demand for SPECT and PET applications along with the growing public awareness for healthcare are fuelling the growth of the market. Further, new developments such as Integration of X ray tomography (CT) into SPECT provide an excellent diagnostic tool in medical imaging and are considered to be a driving factor for the growth of the market. Strict regulatory framework poses a potential hurdle to translational research and clinical investigations. Reimbursement issues are also blocking the growth of the market. In addition, shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are the key factors restraining the Asia-Pacific nuclear medicine Radioisotopes market.
Get accurate market forecast and analysis on the Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market. Request a sample to stay up-to-date on the main trends affecting this market: http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/request-sample
Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market: Segmentation
By Type
● Diagnostic Radioisotopes
o SPECT
● Technetium-99m
● Thallium-201
● Gallium-67
● Iodine-23
● Others
o PET
● Fluorine-18
● Rubidium-82
● Others
● Therapeutic Radioisotopes
o Beta Emitters
● Iodine-131
● Yttrium-90
● Samarium-153
● Rhenium-186
● Lutetium-177
o Alpha Emitters
● Radium-223
o Brachytherapy
● Cesium-131
● Iodine-125
● Palladium-103
● Iridium-192
By Application
● Cardiology
● Lymphoma
● Thyroid
● Neurology
● Oncology
● Others
From simple data collation through secondary and primary research to ad-hoc research requests relating to specific information, we provide our services via customization. Get customization at: http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/customize-report
Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market: Overview
Radiopharmaceuticals are pharmaceutical definitions involving radioactive isotopes that are utilized as a part of determination and therapeutics. They are simple and little substances that contain a radioactive substance that is utilized as a part of the treatment of disease and cardiovascular and neurological disorders.
The ordinary chemotherapy techniques are being replaced by more helpful therapeutic radiopharmaceuticals for oncology and cancer treatment, which opens up new avenues in the radiopharmaceuticals market. Additionally, it helps doctors amid diagnosis, as well as acts as an advantageous and more secure option for patients when compared with X-Rays and other radiation imaging gadgets. Radiopharmaceuticals, otherwise called atomic drugs, are utilized in applications like lymphoma and bone metastasis.
Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market: Region-wise Outlook
On the basis of geography, the Asia-Pacific Market is segmented into various regions namely, India, China, Japan and South Korea. India and China hold a potential market for radioisotope due to growing healthcare sector and increasing demand for different radioisotopes in various treatments and applications.
Key Questions Answered:
● What is the current and future Nuclear Medicine Radiopharmaceuticals Market outlook in Asia-Pacific? What trends are affecting the Asia-Pacific market?
● What is the competitive landscape and market share of major players in the Nuclear Medicine Radiopharmaceuticals in Asia-Pacific?
● What are the key, high growth markets that Nuclear Medicine Radiopharmaceuticals manufacturers should expand into? Which market segments are growing the fastest?
● What are the unmet needs with the Nuclear Medicine Radiopharmaceuticals currently on the market? How will emerging technologies fulfill these unmet needs?
● What is physician perception and market outlook of Nuclear Medicine Radiopharmaceuticals?
● What are the challenges and barriers that have hindered widespread adoption of Nuclear Medicine Radiopharmaceuticals?
Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market: Key Players
Some of the key players influencing the Asia-Pacific nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation, Positron Corporation, Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
Reasons to buy Asia-Pacific Nuclear Medicine Radiopharmaceuticals Market report:
● Regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is prospering
● Segment-level analysis on basis of product type, application, colour along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail
● Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
● Study of macro and micro environmental factors that affect the market presented in an extensive strategic analyses section containing PESTLE and Porter’s Five Forces Analyses
● A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and Analyst overview to study and sustain the market environment
● Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
● Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
Check out other related studies in the Pharmaceuticals Segment:
1. Nuclear Medicine Radiopharmaceuticals Market: http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/
2. Asia-Pacific Antacid Market: http://www.marketdataforecast.com/market-reports/asia-pacific-antacid-market-2363/
3. Asia-Pacific Generic Drugs Market: http://www.marketdataforecast.com/market-reports/asia-pacific-generic-drugs-market-2186/
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com.
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
